Related references
Note: Only part of the references are listed.Salvage therapy with single agent bevacizumab for recurrent glioblastoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Bevacizumab for Recurrent Alkylator-Refractory Anaplastic Oligodendroglioma
Marc C. Chamberlain et al.
CANCER (2009)
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
R. M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival
Ashwatha Narayana et al.
JOURNAL OF NEUROSURGERY (2009)
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Eudocia C. Quant et al.
NEURO-ONCOLOGY (2009)
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
S. Taillibert et al.
NEUROLOGY (2009)
Bevacizumab and chemotherapy for recurrent glioblastoma A single-institution experience
P. L. Nghiemphu et al.
NEUROLOGY (2009)
Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors
Felix Bokstein et al.
CANCER (2008)
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Annick Desjardins et al.
CLINICAL CANCER RESEARCH (2008)
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan
Sith Sathornsumetee et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
Tyler Y. Kang et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay
Ola Soderberg et al.
METHODS (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Karla V. Ballman et al.
NEURO-ONCOLOGY (2007)
Direct observation of individual endogenous protein complexes in situ by proximity ligation
Ola Soderberg et al.
NATURE METHODS (2006)
MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy
WB Pope et al.
NEUROLOGY (2006)
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
HS Phillips et al.
CANCER CELL (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Protein detection using proximity-dependent DNA ligation assays
S Fredriksson et al.
NATURE BIOTECHNOLOGY (2002)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)